Выбор анальгетика при боли в спине сквозь призму лекарственной безопасности и коморбидности: в фокусе – флупиртин
Выбор анальгетика при боли в спине сквозь призму лекарственной безопасности и коморбидности: в фокусе – флупиртин
Трухан Д.И. Выбор анальгетика при боли в спине сквозь призму лекарственной безопасности и коморбидности: в фокусе – флупиртин. Consilium Medicum. 2017; 19 (9): 80–87. DOI: 10.26442/2075-1753_19.9.80-87
________________________________________________
Trukhan D.I. The choice of analgesic for back pain through the prism of drug safety and comorbidity: in the focus of flupirtine. Consilium Medicum. 2017; 19 (9): 80–87. DOI: 10.26442/2075-1753_19.9.80-87
Выбор анальгетика при боли в спине сквозь призму лекарственной безопасности и коморбидности: в фокусе – флупиртин
Трухан Д.И. Выбор анальгетика при боли в спине сквозь призму лекарственной безопасности и коморбидности: в фокусе – флупиртин. Consilium Medicum. 2017; 19 (9): 80–87. DOI: 10.26442/2075-1753_19.9.80-87
________________________________________________
Trukhan D.I. The choice of analgesic for back pain through the prism of drug safety and comorbidity: in the focus of flupirtine. Consilium Medicum. 2017; 19 (9): 80–87. DOI: 10.26442/2075-1753_19.9.80-87
Боль в спине (дорсалгия) беспокоит в разные периоды жизни подавляющее большинство людей, занимая по распространенности 2-е место после простудных заболеваний. Наиболее популярным классом лекарств, применяемых в качестве анальгетиков при дегенеративных или воспалительных заболеваниях опорно-двигательного аппарата, являются нестероидные противовоспалительные препараты (НПВП). Однако с приемом НПВП ассоциируется целый спектр различных осложнений. Лекарственная безопасность и коморбидность тесно переплетаются при использовании НПВП. В представленном обзоре проанализированы отечественные и зарубежные исследования флупиртина для лечения болевого синдрома. Флупиртин выгодно отличается от НПВП и опиоидных анальгетиков сочетанием болеутоляющего и миорелаксирующего свойств, отсутствием лекарственных взаимодействий и серьезных побочных эффектов, что позволяет использовать препарат для лечения болевого синдрома у пациентов с коморбидной соматической патологией.
Back pain (dorsalgia) worries at various periods of life the vast majority of people, occupying the second most common after colds. The most popular class of drugs used as analgesics for degenerative or inflammatory diseases of the musculoskeletal system are nonsteroidal anti-inflammatory drugs (NSAIDs). However, with the intake of NSAIDs, a whole range of different complications is associated. Drug safety and comorbidity are closely intertwined when using NSAIDs. In the presented review, domestic and foreign studies of flupirtine for the treatment of pain syndrome are analyzed. Flupirtine compares favorably with NSAIDs and opioid analgesics with a combination of analgesic and muscle relaxant properties, lack of drug interactions and serious side effects, which makes it possible to use the drug to treat the pain syndrome in patients with comorbid somatic pathology.
1. Трухан Д.И. Выбор лекарственного препарата с позиций рациональной фармакотерапии. Consilium Medicum. 2013; 11: 45–9. / Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 11: 45–9. [in Russian]
2. Трухан Д.И. Рациональная фармакотерапия в кардиологии сквозь призму коморбидности и лекарственной безопасности. Справочник поликлинического врача. 2015; 1: 26–31. / Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
3. Лазебник Л.Б. Полиморбидность и старение. Новости медицины и фармации. 2007; 1 (205). URL: http://archive.today/smbi / Lazebnik L.B. Polimorbidnost' i starenie. Novosti meditsiny i farmatsii. 2007; 1 (205). URL: http://archive.today/smbi [in Russian]
4. Белялов Ф.И. Двенадцать тезисов коморбидности. Клин. медицина. 2009; 12: 69–71. / Belialov F.I. Dvenadtsat' tezisov komorbidnosti. Klin. meditsina. 2009; 12: 69–71. [in Russian]
5. Цурко В.В. Дорсопатия у пожилых: патобиология и комплексная терапия в клинической практике. Терапевт. арх. 2012; 10: 119–24. / Tsurko V.V. Dorsopatiia u pozhilykh: patobiologiia i kompleksnaia terapiia v klinicheskoi praktike. Terapevt. arkh. 2012; 10: 119–24. [in Russian]
6. Котова О.В., Воробьева О.В. Остеохондроз как причина дорсопатии. Consilium Medicum (Прил. Неврология и Ревматология). 2012; 2: 80–3. / Kotova O.V., Vorob'eva O.V. Osteokhondroz kak prichina dorsopatii. Consilium Medicum (Suppl. Neurology and Rheumatology). 2012; 2: 80–3. [in Russian]
7. Пимонова И. Лечение дорсалгии на амбулаторно-поликлиническом этапе в городской больнице. Врач. 2010; 3: 70–3. / Pimonova I. Lechenie dorsalgii na ambulatorno-poliklinicheskom etape v gorodskoi bol'nitse. Vrach. 2010; 3: 70–3. [in Russian]
8. Бойцов И.В. Дорсопатии шейного, грудного, поясничного отделов позвоночника: особенности неврологических осложнений (обзор литературы). Справ. врача общей практики. 2013; 5: 73–8. / Boitsov I.V. Dorsopatii sheinogo, grudnogo, poiasnichnogo otdelov pozvonochnika: osobennosti nevrologicheskikh oslozhnenii (obzor literatury). Sprav. vracha obshchei praktiki. 2013; 5: 73–8. [in Russian]
9. Трухан Д.И. Дорсалгия: актуальные аспекты лечения на амбулаторно-поликлиническом этапе. Справочник поликлинического врача. 2017; 2: 78–83. / Trukhan D.I. Dorsalgia: actual aspects of treatment at the ambulatory-polyclinic stage. Handbook for Practitioners Doctors. 2017; 2: 78–83. [in Russian]
10. Манвелов Л.С., Тюрников В.М. Поясничные боли (этиология, клиника, диагностика и лечение). Рус. мед. журн. 2009; 20: 1290–4. / Manvelov L.S., Tiurnikov V.M. Poiasnichnye boli (etiologiia, klinika, diagnostika i lechenie). Rus. med. zhurn. 2009; 20: 1290–4. [in Russian]
11. Трухан Д.И. Скелетно-мышечные боли: актуальные аспекты лечения на этапе оказания первичной медико-санитарной помощи. Consilium Medicum. 2017; 19 (2): 129–35. / Trukhan D.I. Musculoskeletal pain: actual aspects of treatment at the stage of primary medical care. Consilium Medicum. 2017; 19 (2): 129–135. [in Russian]
12. Подчуфарова Е.В. Скелетно-мышечные боли в спине. РМЖ. 2005; 12: 836–40. / Podchufarova E.V. Skeletno-myshechnye boli v spine. RMZh. 2005; 12: 836–40. [in Russian]
13. Котов А.С., Елисеев Ю.В. Поясничная боль. Журн. неврологии и психиатрии им. С.С.Корсакова. 2012; 5: 90–3. / Kotov A.S., Eliseev Iu.V. Poiasnichnaia bol'. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2012; 5: 90–3. [in Russian]
14. Рачин А.П., Якунин К.А., Демешко А.В. Миофасциальный болевой синдром. М.: ГЭОТАР-Медиа, 2011. / Rachin A.P., Iakunin K.A., Demeshko A.V. Miofastsial'nyi bolevoi sindrom. M.: GEOTAR-Media, 2011. [in Russian]
15. Тревелл Дж. Г., Симонс Д.Г. Миофасциальные боли. Т. 1. М.: Медицина, 1989. / Trevell Dzh. G., Simons D.G. Miofastsial'nye boli. T. 1. M.: Meditsina, 1989. [in Russian]
16. Вознесенская Т.Г. Миофасциальные болевые синдромы. Consilium Medicum. 2002; 4 (8).URL: http://con-med.ru/magazines/consilium_medicum/consilium_medicum-08-2002/ / Voznesenskaia T.G. Miofastsial'nye bolevye sindromy. Consilium Medicum. 2002; 4 (8). URL: http://con-med.ru/magazines/consilium_medicum/consilium_medicum-08-2002/ [in Russian]
17. Воробьева О.В. Скелетная мускулатура как причина локальных болевых синдромов. Consilium Medicum. 2012; 14 (2). / Vorobeva O.V. Skeletnaia muskulatura kak prichina lokal'nykh bolevykh sindromov. Consilium Medicum. 2012; 14 (2). URL: http://con-med.ru/magazines/consilium_medicum/consilium_medicum-02-2012/ [in Russian]
18. Насонов Е.Л., Каратеев А.Е. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. РМЖ. 2006; 25. / Nasonov E.L., Karateev A.E. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii. RMZh. 2006; 25. URL: http://rmj.ru/articles_4309.htm [in Russian]
19. Трухан Д.И., Давыдов Е.Л. Дорсалгия: актуальные аспекты терапии на этапе оказания первичной медико-санитарной помощи. Consilium Medicum. 2015; 17 (9): 82–7. / Trukhan D.I., Davydov E.L. Dorsalgia: topical aspects of treatment at stages of primary health care. Consilium Medicum. 2015; 17 (9): 82–7. [in Russian]
20. Ревматология. Национальное руководство. Под ред. Е.Л.Насонова. М.: ГЭОТАР-Медиа, 2008. / Revmatologiia. Natsionalnoe rukovodstvo. Pod red. E.L.Nasonova. M.: GEOTAR-Media, 2008 [in Russian]
21. Рациональная фармакотерапия ревматических заболеваний. Руководство для практикующих врачей. Под общ. ред. В.А.Насоновой, Е.Л.Насонова. М.: Литтерра, 2007. / Ratsionalnaia farmakoterapiia revmaticheskikh zabolevanii: Rukovodstvo dlia praktikuiushchikh vrachei. Pod obshch. red. V.A.Nasonovoi, E.L.Nasonova. M.: Litterra, 2007. [in Russian]
22. Насонов Е.Л., Каратеев А.Е. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Рус. мед. журн. 2006; 25: 1769–77. / Nasonov E.L., Karateev A.E. Primenenie nesteroidnykh protivovospalitelnykh preparatov. Klinicheskie rekomendatsii. Rus. med. zhurn. 2006; 25: 1769–77. [in Russian]
23. Каратеев А.Е., Насонов Е.Л. НПВП – ассоциированная патология ЖКТ: реальное состояние дел в России. Рус. мед. журн. 2006; 15: 1073–8. / Karateev A.E., Nasonov E.L. NPVP – assotsiirovannaia patologiia ZhKT: realnoe sostoianie del v Rossii. Rus. med. zhurn. 2006; 15: 1073–8. [in Russian]
24. Трухан Д.И., Викторова И.А. Внутренние болезни. Кардиология. Ревматология. М.: Мед. информагентство, 2013. / Trukhan D.I., Viktorova I.A. Vnutrennie bolezni. Kardiologiia. Revmatologiia. M.: Med. informagentstvo, 2013. [in Russian]
25. Верткин А.Л., Носова А.В., Алисов В.А., Заиченко Д.М. Выбор нестероидных противовоспалительных препаратов для купирования болевого синдрома в клинической практике. Consilium Medicum. 2013; 15 (8): 63–7. / Vertkin A.L., Nosova A.V., Alisov V.A., Zaichenko D.M. Vybor nesteroidnykh protivovospalitelnykh preparatov dlia kupirovaniia bolevogo sindroma v klinicheskoi praktike. Consilium Medicum. 2013; 15 (8): 63–7. [in Russian]
26. Трухан Д.И., Филимонов С.Н., Викторова И.А. Клиника, диагностика и лечение основных ревматических болезней. СПб.: СпецЛит, 2014. / Trukhan D.I., Filimonov S.N., Viktorova I.A. Klinika, diagnostika i lechenie osnovnykh revmaticheskikh boleznei. SPb.: SpetsLit, 2014. [in Russian]
27. Лапина Т.Л. Гастропатия, индуцированная нестероидными противовоспалительными препаратами: пути решения проблемы. Рус. мед. журн. 2009; 2: 54–7. / Lapina T.L. Gastropatiia, indutsirovannaia nesteroidnymi protivovospalitelnymi preparatami: puti resheniia problemy. Rus. med. zhurn. 2009; 2: 54–7. [in Russian]
28. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Соврем. ревматология. 2015; 9 (1): 4–23. / Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii «Ratsionalnoe primenenie nesteroidnykh protivovospalitelnykh preparatov (NPVP) v klinicheskoi praktike». Sovrem. revmatologiia. 2015; 9 (1): 4–23. [in Russian]
29. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety. Clin Interv Aging 2011; 6: 125–31.
30. Roth SH. Coming to terms with nonsteroidal anti-inflammatory drug gastropathy. Drugs 2012; 72 (7): 873–9.
31. Трухан Д.И. Выбор нестероидного противовоспалительного препарата с позиций профилактики НПВП-гастропатии и лекарственной безопасности. Consilium Medicum. 2014; 16 (8): 14–9. / Trukhan D.I. Vybor nesteroidnogo protivovospalitelnogo preparata s pozitsii profilaktiki NPVP-gastropatii i lekarstvennoi bezopasnosti. Consilium Medicum. 2014; 16 (8): 14–9. [in Russian]
32. Трухан Д.И. Нестероидные противовоспалительные препараты сквозь призму коморбидности и лекарственной безопасности: в фокусе – амтолметин гуацил. Consilium Medicum. 2015; 17 (2): 27–33. / Trukhan D.I. Nonsteroidal anti-inflammatory drugs through the prism comorbidity and drug safety: in focus amtolmetin guatsil. Consilium Medicum. 2015; 17 (2): 27–33. [in Russian]
33. Вялов С.С. Противовоспалительная терапия и гастротоксичность: реальные возможности профилактики. Рус. мед. журн. 2014; 22. / Vialov S.S. Protivovospalitelnaia terapiia i gastrotoksichnost: realnye vozmozhnosti profilaktiki. Rus. med. zhurn. 2014; 22. URL: http://rmj.ru/articles_9750.htm [in Russian]
34. Antman EM, Bennett JS, Daugherty A et al. Use of nonsteroidal antiinflammatory drugs. An Update for Clinicians. A Scientific Statement from the American Heart Association. Circulation 2007; 115: 1634–42.
35. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894–909.
36. Lanza FL, Chan FK, Quigley EM. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104: 728–38.
37. Chan FK, Abraham NS, Scheiman JM, Laine L. Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008; 103: 2908–18.
38. Пахомова И.Г. Новые возможности в минимизации риска НПВП-индуцированных гастропатий. Рус. мед. журн. 2014; 10: 772–6. / Pakhomova I.G. Novye vozmozhnosti v minimizatsii riska NPVP-indutsirovannykh gastropatii. Rus. med. zhurn. 2014; 10: 772–6. [in Russian]
39. Плотникова Е.Ю., Грачева Т.Ю. Эрозивно-язвенные поражения желудочно-кишечного тракта и простагландины: проблемный дуэт. Справочник поликлинического врача. 2016; 4: 32–7. / Plotnikova E.Iu., Gracheva T.Iu. Erozivno-iazvennye porazheniia zheludochno-kishechnogo trakta i prostaglandiny: problemnyi duet. Handbook for Practitioners Doctors. 2016; 4: 32–7. [in Russian]
40. Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 29 (5): 481–96.
41. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010; 32 (4): 667–77.
42. Каратеев А.Е. Что лучше для профилактики НПВП-гастропатии: коксибы или комбинация «традиционных» НПВП и гастропротектора? Рус. мед. журн. 2013; 13. / Karateev A.E. Chto luchshe dlia profilaktiki NPVP-gastropatii: koksiby ili kombinatsiia «traditsionnykh» NPVP i gastroprotektora? Rus. med. zhurn. 2013; 13. URL: http://rmj.ru/articles_8770.htm [in Russian]
43. Popular heartburn medication may increase ischemic stroke risk. American Heart Association Meeting Report – Presentation: 391–Session: EP.AOS.765. URL: http://newsroom.heart.org/news/Xpopular-heartburn-medication-may-increase-ischemic-stroke-risk
44. Xie Y, Bowe B, Li T et al. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open 2017; 7 (6): e015735. DOI: 10.1136/bmjopen-2016-015735
45. Трухан Д.И., Тарасова Л.В. Рациональная фармакотерапия и лекарственная безопасность в кардиологии. Справочник поликлинического врача. 2013; 5: 21–6. / Trukhan D.I., Tarasova L.V. Ratsionalnaia farmakoterapiia i lekarstvennaia bezopasnost v kardiologii. Handbook for Practitioners Doctors. 2013; 5: 21–6. [in Russian]
46. FDA Public Health Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). URL:http://www.fda.gov/ cder/drug/advisory/ COX2.htm
47. Пиманов С.И., Дикарева Е.А., Макаренко Е.В. Как уменьшить гастроинтестинальный риск при использовании нестероидных противовоспалительных препаратов? Consilium Medicum. 2014; 16 (2): 95–9. / Pimanov S.I., Dikareva E.A., Makarenko E.V. Kak umenshit gastrointestinalnyi risk pri ispolzovanii nesteroidnykh protivovospalitelnykh preparatov? Consilium Medicum. 2014; 16 (2): 95–9. [in Russian]
48. Gislason G, Jacobsen S, Rasmussen J et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflam-matory drugs after acute myocardial infarction. Circulation 2006; 113 (25): 2906–13.
49. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086. URL: http://www.bmj.com/content/342/bmj.c7086
50. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (4-й пересмотр). Сердечная недостаточность. 2013; 7 (81): 379–472. / Mareev V.Iu., Ageev F.T., Arutiunov G.P. i dr. Natsionalnye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (4-i peresmotr). Serdechnaia nedostatochnost. 2013; 7 (81): 379–472. [in Russian]
51. Котова О.В., Акарачкова Е.С. Место препарата нолодатак в лечении боли в спине. Фарматека. 2015; 13 (306): 70–3. / Kotova O.V., Akarachkova E.S. Mesto preparata nolodatak v lechenii boli v spine. Farmateka. 2015; 13 (306): 70–3. [in Russian]
52. Каратеев А.Е. Что может стать альтернативой нестероидным противовоспалительным препаратам для контроля острой скелетно-мышечной боли у пациента, имевшего в анамнезе инфаркт миокарда и желудочно-кишечное кровотечение? Consilium Medicum. 2016; 18 (2): 141–9. / Karateev A.E. What can be an alternative to non-steroidal anti-inflammatory drugs for the control of acute musculoskeletal pain in a patient with a history of myocardial infarction and gastrointestinal bleeding? Consilium Medicum. 2016; 18 (2): 141–9. [in Russian]
53. Магомедова М., Камчатнов П. Эффективность и безопасность лечения пациентов с поясничной болью. Врач. 2016; 3: 29–31. / Magomedova M., Kamchatnov P. Effektivnost i bezopasnost lecheniia patsientov s poiasnichnoi boliu. Vrach. 2016; 3: 29–31. [in Russian]
54. Котова О.В., Акарачкова Е.С. Боль в шее: возможности терапии. Терапия. 2016; 2 (6): 70–5. / Kotova O.V., Akarachkova E.S. Bol v shee: vozmozhnosti terapii. Terapiia. 2016; 2 (6): 70–5. [in Russian]
55. Подымова И.Г., Данилов А.Б. Особенности терапии боли в нижней части спины у пациентов с противопоказаниями к нестероидным противовоспалительным препаратам. Consilium Medicum. 2016; 18 (2): 50–2. / Podymova I.G., Danilov A.B. Features of treatment of pain in the lower back in patients with contraindications for nonsteroidal anti-inflammatory drugs. Consilium Medicum. 2016; 18 (2): 50–2. [in Russian]
56. Камчатнов П.Р., Магомедова М.А., Чугунов А.В. Проблема эффективности и безопасности лечения пациента с поясничной болью. Терапия. 2016; 1: 75–81. / Kamchatnov P.R., Magomedova M.A., Chugunov A.V. Problema effektivnosti i bezopasnosti lecheniia patsienta s poiasnichnoi boliu. Terapiia. 2016; 1: 75–81. [in Russian]
57. Азимова Ю.Э. Боль в спине: бремя сопутствующих заболеваний и подбор эффективной терапии. Терапия. 2017; 1: 144–8. / Azimova Iu.E. Bol v spine: bremia soputstvuiushchikh zabolevanii i podbor effektivnoi terapii. Terapiia. 2017; 1: 144–8. [in Russian]
58. Камчатнов П.Р., Ханмурзаева Н.Б., Ханмурзаева С.Б. Нолодотак (флупиртин) в лечении пациентов с дорсопатией. Терапия. 2017; 3: 76–83. / Kamchatnov P.R., Khanmurzaeva N.B., Khanmurzaeva S.B. Nolodotak (flupirtin) v lechenii patsientov s dorsopatiei. Terapiia. 2017; 3: 76–83. [in Russian]
59. Ueberall MА, Mueller-Schwefe GН, Terhaag B. Efficacy and tolerability of flupirtine in subacute / chronic musculoskeletal pain – results of a patient level, pooled reanalysis of randomized, doubleblind, controlled trials. Int J Clin Pharmacol Ther 2011; 49: 637–47.
60. Jakob R, Krieglstein J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurons. Br J Pharmacol 1997; 122: 1333–8.
61. Kornhuber J, Bleich S, Wiltfang J et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg+ block via activation of voltage independent potassium channels. J Neural Transm 1999; 106 (9–10): 857–67.
62. Wörz R, Müller-Schwefe G, Stroehmann I et al. Back pain: Guidelines for drug therapy. Fortschr Med 2000; 142 (5): 27–33.
63. Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res 2013 Mar; 62 (3): 251–8.
64. Wörz R, Bolten W, Heller B et al. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996; 114 (35–36): 500–4.
65. Perovic S, Pialoglou P, Schroder HC et al. Flupirtine increases the levels of glutathione and Bc1–2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect. Eur J Pharmacol 1996; 317 (1): 157–64.
66. Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert Opin Pharmacother 2009; 10 (9): 1495–500.
67. Devulder J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs 2010; 24 (10): 867–81.
68. Raffa RB, Pergolizzi JV Jr. The evolving understanding of the analgesic mechanism of action of flupirtine. J Clin Pharm Ther 2012; 37 (1): 4–6.
69. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study. Fortschr Med Orig 2003; 121 (1): 11–8.
70. Ringe JD et al. Analgesic Efficacy of Flupirtine in Primary Care of Patients with Osteoporosis Related Pain. A multivariate analysis. Arzneimittelforschung 2003; 53 (7): 496–502.
71. Левин Я.И., Стрыгин К.Н., Добровольская Л.Е. Катадолон в лечении боли в спине. Лечение нервных болезней. 2005; 6 (3): 12–7. / Levin Ia.I., Strygin K.N., Dobrovolskaia L.E. Katadolon v lechenii boli v spine. Lechenie nervnykh boleznei. 2005; 6 (3): 12–7. [in Russian]
72. Камчатнов П.Р., Батышева Т.Т., Ганжула П.А. и др. Применение катадолона у больных со спондилогенной дорсалгией. Журн. неврологии и психиатрии им. С.С.Корсакова. 2006; 106 (11): 46–8. / Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. i dr. Primenenie katadolona u bolnykh so spondilogennoi dorsalgiei. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2006; 106 (11): 46–8. [in Russian]
73. Эрдес Ш., Галушко Е., Зоткин Е. и др. Эффективность катадолона (флупиртина) у пациентов с болями в нижней части спины. Врач. 2007; 5: 56–9. / Erdes Sh., Galushko E., Zotkin E. i dr. Effektivnost katadolona (flupirtina) u patsientov s boliami v nizhnei chasti spiny. Vrach. 2007; 5: 56–9. [in Russian]
74. Алексеев В.В., Рачин А.П., Подчуфарова Е.В. Флупиртин (Катадолон) – нестандартный подход в терапии боли. Неврол. и ревматология. 2009; 2: 50–3. / Alekseev V.V., Rachin A.P., Podchufarova E.V. Flupirtin (Katadolon) – nestandartnyi podkhod v terapii boli. Nevrol. i revmatologiia. 2009; 2: 50–3. [in Russian]
75. Данилов А.Б., Николаева Н.С. Эффективность новой формы флупиртина (Катадолона форте) в лечении острой боли в спине. Managepain. 2013; 1: 44–8. / Danilov A.B., Nikolaeva N.S. Effektivnost novoi formy flupirtina (Katadolona forte) v lechenii ostroi boli v spine. Managepain. 2013; 1: 44–8. [in Russian]
76. Yadav G, Behera SS, Das SK et al. Role of flupirtine as a preemptive analgesic in patients undergoing laparoscopic cholecystectomy. J Anaesthesiol Clin Pharmacol 2015; 31 (2): 169–73.
77. Ueberall MA, Essner U, Müller-Schwefe GH. 2-week efficacy and tolerability of flupirtine MR and diclofenac in patients with acute low/back pain-results of a post-hoc subgroup analysis of patient-level data from four non-interventional studies. MMW Fortschr Med 2013; 155 (Suppl. 4): 115–23.
78. Li C, Ni J, Wang Z et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 24 (12): 3523–30.
79. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr Med Res Opin 2012; 28 (10): 1617–34.
80. Рачин А.П. Десять доказательств успешного применения флупиртина (катадолона) при болях в нижней части спины. Лечение нервных болезней. 2007; 2: 35–9. / Rachin A.P. Desiat dokazatelstv uspeshnogo primeneniia flupirtina (katadolona) pri boliakh v nizhnei chasti spiny. Lechenie nervnykh boleznei. 2007; 2: 35–9. [in Russian]
81. Restrictions in the use of flupirtine-containing medicines – CMDh endorses PRAC recommendation. Press release. 28/06/2013. URL: http://www.ema.europa.eu/ema/
index.jsp curl=pages/news_and_events/news/2013/06/news_detail_001831.jsp&mid=WC0b01ac058004d5c1
82. Restrictions in the use of flupirtine-containing medicines. 13 September 2013. EMA/563900/ 2013. URL: http://www.ema.europa.eu/docs/en_GB/document_library/ Referrals_document/Flupirtine-containing_medicines/European_Commission_final_decision/ WC500155310.pdf
83. Harish S, Bhuvana K, Bengalorkar GM, Kumar T. Flupirtine: Clinical pharmacology. J Anaesth Clin Pharmacol 2012; 28: 172–7.
84. Treudler R, Pohle K, Simon JC. Flupirtine is a safe alternative drug in patients with hypersensitivity to NSAIDs. Eur J Clin Pharmacol 2011; 67 (9): 961–3.
85. Flupirtine (флупиртин). URL: https://www.vidal.ru/drugs/molecule/1338 / Flupirtine (flupirtin). URL: https://www.vidal.ru/drugs/molecule/1338 [in Russian]
86. Wörz R. Long-term-treatment of chronic pain patients with flupirtine – on hepatotoxicity and persistent effectiveness from 7 months to 22 years. MMW Fortschr Med 2014; 156 (Suppl. 4): 127–34.
87. Nicoletti P, Werk A, Sawle A et al. International Drug-induced Liver Injury Consortium. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics 2016; 26 (5): 218–24.
88. Трухан Д.И. Рациональная фармакотерапия в гастроэнтерологии. Справочник поликлинического врача. 2012; 10: 18–24. / Trukhan D.I. Ratsionalnaia farmakoterapiia v gastroenterologii. Handbook for Practitioners Doctors. 2012; 10: 18–24. [in Russian]
89. Тарасова Л.В., Трухан Д.И. Лекарственная безопасность в гастроэнтерологии. Эксперим. и клин. гастроэнтерология. 2013; 4: 81–7. / Tarasova L.V., Trukhan D.I. Lekarstvennaia bezopasnost v gastroenterologii. Eksperim. i klin. gastroenterologiia. 2013; 4: 81–7. [in Russian]
90. Трухан Д.И, Тарасова Л.В. Лекарственная безопасность и рациональная фармакотерапия в гастроэнтерологической практике. Клин. перспективы гастроэнтерологии, гепатологии. 2013; 5: 9–16. / Trukhan D.I, Tarasova L.V. Lekarstvennaia bezopasnost i ratsionalnaia farmakoterapiia v gastroenterologicheskoi praktike. Klin. perspektivy gastroenterologii, gepatologii. 2013; 5: 9–16. [in Russian]
________________________________________________
1. Trukhan D.I. Vybor lekarstvennogo preparata s pozitsii ratsional'noi farmakoterapii. Consilium Medicum. 2013; 11: 45–9. [in Russian]
2. Trukhan D.I. Ratsional'naia farmakoterapiia v kardiologii skvoz' prizmu komorbidnosti i lekarstvennoi bezopasnosti. Handbook for Practitioners Doctors. 2015; 1: 26–31. [in Russian]
3. Lazebnik L.B. Polimorbidnost' i starenie. Novosti meditsiny i farmatsii. 2007; 1 (205). URL: http://archive.today/smbi [in Russian]
4. Belialov F.I. Dvenadtsat' tezisov komorbidnosti. Klin. meditsina. 2009; 12: 69–71. [in Russian]
5. Tsurko V.V. Dorsopatiia u pozhilykh: patobiologiia i kompleksnaia terapiia v klinicheskoi praktike. Terapevt. arkh. 2012; 10: 119–24. [in Russian]
6. Kotova O.V., Vorob'eva O.V. Osteokhondroz kak prichina dorsopatii. Consilium Medicum (Suppl. Neurology and Rheumatology). 2012; 2: 80–3. [in Russian]
7. Pimonova I. Lechenie dorsalgii na ambulatorno-poliklinicheskom etape v gorodskoi bol'nitse. Vrach. 2010; 3: 70–3. [in Russian]
8. Boitsov I.V. Dorsopatii sheinogo, grudnogo, poiasnichnogo otdelov pozvonochnika: osobennosti nevrologicheskikh oslozhnenii (obzor literatury). Sprav. vracha obshchei praktiki. 2013; 5: 73–8. [in Russian]
9. Trukhan D.I. Dorsalgia: actual aspects of treatment at the ambulatory-polyclinic stage. Handbook for Practitioners Doctors. 2017; 2: 78–83. [in Russian]
10. Manvelov L.S., Tiurnikov V.M. Poiasnichnye boli (etiologiia, klinika, diagnostika i lechenie). Rus. med. zhurn. 2009; 20: 1290–4. [in Russian]
11. Trukhan D.I. Musculoskeletal pain: actual aspects of treatment at the stage of primary medical care. Consilium Medicum. 2017; 19 (2): 129–135. [in Russian]
12. Podchufarova E.V. Skeletno-myshechnye boli v spine. RMZh. 2005; 12: 836–40. [in Russian]
13. Kotov A.S., Eliseev Iu.V. Poiasnichnaia bol'. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2012; 5: 90–3. [in Russian]
14. Rachin A.P., Iakunin K.A., Demeshko A.V. Miofastsial'nyi bolevoi sindrom. M.: GEOTAR-Media, 2011. [in Russian]
15. Trevell Dzh. G., Simons D.G. Miofastsial'nye boli. T. 1. M.: Meditsina, 1989. [in Russian]
16. Voznesenskaia T.G. Miofastsial'nye bolevye sindromy. Consilium Medicum. 2002; 4 (8). URL: http://con-med.ru/magazines/consilium_medicum/consilium_medicum-08-2002/ [in Russian]
17. Vorobeva O.V. Skeletnaia muskulatura kak prichina lokal'nykh bolevykh sindromov. Consilium Medicum. 2012; 14 (2). URL: http://con-med.ru/magazines/consilium_medicum/consilium_medicum-02-2012/ [in Russian]
18. Nasonov E.L., Karateev A.E. Primenenie nesteroidnykh protivovospalitel'nykh preparatov. Klinicheskie rekomendatsii. RMZh. 2006; 25. URL: http://rmj.ru/articles_4309.htm [in Russian]
19. Trukhan D.I., Davydov E.L. Dorsalgia: topical aspects of treatment at stages of primary health care. Consilium Medicum. 2015; 17 (9): 82–7. [in Russian]
20. Revmatologiia. Natsionalnoe rukovodstvo. Pod red. E.L.Nasonova. M.: GEOTAR-Media, 2008 [in Russian]
21. Ratsionalnaia farmakoterapiia revmaticheskikh zabolevanii: Rukovodstvo dlia praktikuiushchikh vrachei. Pod obshch. red. V.A.Nasonovoi, E.L.Nasonova. M.: Litterra, 2007. [in Russian]
22. Nasonov E.L., Karateev A.E. Primenenie nesteroidnykh protivovospalitelnykh preparatov. Klinicheskie rekomendatsii. Rus. med. zhurn. 2006; 25: 1769–77. [in Russian]
23. Karateev A.E., Nasonov E.L. NPVP – assotsiirovannaia patologiia ZhKT: realnoe sostoianie del v Rossii. Rus. med. zhurn. 2006; 15: 1073–8. [in Russian]
24. Trukhan D.I., Viktorova I.A. Vnutrennie bolezni. Kardiologiia. Revmatologiia. M.: Med. informagentstvo, 2013. [in Russian]
25. Vertkin A.L., Nosova A.V., Alisov V.A., Zaichenko D.M. Vybor nesteroidnykh protivovospalitelnykh preparatov dlia kupirovaniia bolevogo sindroma v klinicheskoi praktike. Consilium Medicum. 2013; 15 (8): 63–7. [in Russian]
26. Trukhan D.I., Filimonov S.N., Viktorova I.A. Klinika, diagnostika i lechenie osnovnykh revmaticheskikh boleznei. SPb.: SpetsLit, 2014. [in Russian]
27. Lapina T.L. Gastropatiia, indutsirovannaia nesteroidnymi protivovospalitelnymi preparatami: puti resheniia problemy. Rus. med. zhurn. 2009; 2: 54–7. [in Russian]
28. Karateev A.E., Nasonov E.L., Iakhno N.N. i dr. Klinicheskie rekomendatsii «Ratsionalnoe primenenie nesteroidnykh protivovospalitelnykh preparatov (NPVP) v klinicheskoi praktike». Sovrem. revmatologiia. 2015; 9 (1): 4–23. [in Russian]
29. Roth SH. Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety. Clin Interv Aging 2011; 6: 125–31.
30. Roth SH. Coming to terms with nonsteroidal anti-inflammatory drug gastropathy. Drugs 2012; 72 (7): 873–9.
31. Trukhan D.I. Vybor nesteroidnogo protivovospalitelnogo preparata s pozitsii profilaktiki NPVP-gastropatii i lekarstvennoi bezopasnosti. Consilium Medicum. 2014; 16 (8): 14–9. [in Russian]
32. Trukhan D.I. Nonsteroidal anti-inflammatory drugs through the prism comorbidity and drug safety: in focus amtolmetin guatsil. Consilium Medicum. 2015; 17 (2): 27–33. [in Russian]
33. Vialov S.S. Protivovospalitelnaia terapiia i gastrotoksichnost: realnye vozmozhnosti profilaktiki. Rus. med. zhurn. 2014; 22. URL: http://rmj.ru/articles_9750.htm [in Russian]
34. Antman EM, Bennett JS, Daugherty A et al. Use of nonsteroidal antiinflammatory drugs. An Update for Clinicians. A Scientific Statement from the American Heart Association. Circulation 2007; 115: 1634–42.
35. Bhatt DL, Scheiman J, Abraham NS et al. ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894–909.
36. Lanza FL, Chan FK, Quigley EM. Guidelines for Prevention of NSAID-Related Ulcer Complications. Am J Gastroenterol 2009; 104: 728–38.
37. Chan FK, Abraham NS, Scheiman JM, Laine L. Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008; 103: 2908–18.
38. Pakhomova I.G. Novye vozmozhnosti v minimizatsii riska NPVP-indutsirovannykh gastropatii. Rus. med. zhurn. 2014; 10: 772–6. [in Russian]
39. Plotnikova E.Iu., Gracheva T.Iu. Erozivno-iazvennye porazheniia zheludochno-kishechnogo trakta i prostaglandiny: problemnyi duet. Handbook for Practitioners Doctors. 2016; 4: 32–7. [in Russian]
40. Rostom A, Moayyedi P, Hunt R. Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 29 (5): 481–96.
41. Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther 2010; 32 (4): 667–77.
42. Karateev A.E. Chto luchshe dlia profilaktiki NPVP-gastropatii: koksiby ili kombinatsiia «traditsionnykh» NPVP i gastroprotektora? Rus. med. zhurn. 2013; 13. URL: http://rmj.ru/articles_8770.htm [in Russian]
43. Popular heartburn medication may increase ischemic stroke risk. American Heart Association Meeting Report – Presentation: 391–Session: EP.AOS.765. URL: http://newsroom.heart.org/news/Xpopular-heartburn-medication-may-increase-ischemic-stroke-risk
44. Xie Y, Bowe B, Li T et al. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open 2017; 7 (6): e015735. DOI: 10.1136/bmjopen-2016-015735
45. Trukhan D.I., Tarasova L.V. Ratsionalnaia farmakoterapiia i lekarstvennaia bezopasnost v kardiologii. Handbook for Practitioners Doctors. 2013; 5: 21–6. [in Russian]
46. FDA Public Health Advisory: FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). URL:http://www.fda.gov/ cder/drug/advisory/ COX2.htm
47. Pimanov S.I., Dikareva E.A., Makarenko E.V. Kak umenshit gastrointestinalnyi risk pri ispolzovanii nesteroidnykh protivovospalitelnykh preparatov? Consilium Medicum. 2014; 16 (2): 95–9. [in Russian]
48. Gislason G, Jacobsen S, Rasmussen J et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflam-matory drugs after acute myocardial infarction. Circulation 2006; 113 (25): 2906–13.
49. Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011; 342: 7086. URL: http://www.bmj.com/content/342/bmj.c7086
50. Mareev V.Iu., Ageev F.T., Arutiunov G.P. i dr. Natsionalnye rekomendatsii OSSN, RKO i RNMOT po diagnostike i lecheniiu KhSN (4-i peresmotr). Serdechnaia nedostatochnost. 2013; 7 (81): 379–472. [in Russian]
51. Kotova O.V., Akarachkova E.S. Mesto preparata nolodatak v lechenii boli v spine. Farmateka. 2015; 13 (306): 70–3. [in Russian]
52. Karateev A.E. What can be an alternative to non-steroidal anti-inflammatory drugs for the control of acute musculoskeletal pain in a patient with a history of myocardial infarction and gastrointestinal bleeding? Consilium Medicum. 2016; 18 (2): 141–9. [in Russian]
53. Magomedova M., Kamchatnov P. Effektivnost i bezopasnost lecheniia patsientov s poiasnichnoi boliu. Vrach. 2016; 3: 29–31. [in Russian]
54. Kotova O.V., Akarachkova E.S. Bol v shee: vozmozhnosti terapii. Terapiia. 2016; 2 (6): 70–5. [in Russian]
55. Podymova I.G., Danilov A.B. Features of treatment of pain in the lower back in patients with contraindications for nonsteroidal anti-inflammatory drugs. Consilium Medicum. 2016; 18 (2): 50–2. [in Russian]
56. Kamchatnov P.R., Magomedova M.A., Chugunov A.V. Problema effektivnosti i bezopasnosti lecheniia patsienta s poiasnichnoi boliu. Terapiia. 2016; 1: 75–81. [in Russian]
57. Azimova Iu.E. Bol v spine: bremia soputstvuiushchikh zabolevanii i podbor effektivnoi terapii. Terapiia. 2017; 1: 144–8. [in Russian]
58. Kamchatnov P.R., Khanmurzaeva N.B., Khanmurzaeva S.B. Nolodotak (flupirtin) v lechenii patsientov s dorsopatiei. Terapiia. 2017; 3: 76–83. [in Russian]
59. Ueberall MА, Mueller-Schwefe GН, Terhaag B. Efficacy and tolerability of flupirtine in subacute / chronic musculoskeletal pain – results of a patient level, pooled reanalysis of randomized, doubleblind, controlled trials. Int J Clin Pharmacol Ther 2011; 49: 637–47.
60. Jakob R, Krieglstein J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurons. Br J Pharmacol 1997; 122: 1333–8.
61. Kornhuber J, Bleich S, Wiltfang J et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg+ block via activation of voltage independent potassium channels. J Neural Transm 1999; 106 (9–10): 857–67.
62. Wörz R, Müller-Schwefe G, Stroehmann I et al. Back pain: Guidelines for drug therapy. Fortschr Med 2000; 142 (5): 27–33.
63. Szelenyi I. Flupirtine, a re-discovered drug, revisited. Inflamm Res 2013 Mar; 62 (3): 251–8.
64. Wörz R, Bolten W, Heller B et al. Flupirtine in comparison with chlormezanone in chronic musculoskeletal back pain. Results of a multicenter randomized double-blind study. Fortschr Med 1996; 114 (35–36): 500–4.
65. Perovic S, Pialoglou P, Schroder HC et al. Flupirtine increases the levels of glutathione and Bc1–2 in hNT (human Ntera/D1) neurons: mode of action of the drug-mediated anti-apoptotic effect. Eur J Pharmacol 1996; 317 (1): 157–64.
66. Klawe C, Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound. Expert Opin Pharmacother 2009; 10 (9): 1495–500.
67. Devulder J. Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs 2010; 24 (10): 867–81.
68. Raffa RB, Pergolizzi JV Jr. The evolving understanding of the analgesic mechanism of action of flupirtine. J Clin Pharm Ther 2012; 37 (1): 4–6.
69. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study. Fortschr Med Orig 2003; 121 (1): 11–8.
70. Ringe JD et al. Analgesic Efficacy of Flupirtine in Primary Care of Patients with Osteoporosis Related Pain. A multivariate analysis. Arzneimittelforschung 2003; 53 (7): 496–502.
71. Levin Ia.I., Strygin K.N., Dobrovolskaia L.E. Katadolon v lechenii boli v spine. Lechenie nervnykh boleznei. 2005; 6 (3): 12–7. [in Russian]
72. Kamchatnov P.R., Batysheva T.T., Ganzhula P.A. i dr. Primenenie katadolona u bolnykh so spondilogennoi dorsalgiei. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2006; 106 (11): 46–8. [in Russian]
73. Erdes Sh., Galushko E., Zotkin E. i dr. Effektivnost katadolona (flupirtina) u patsientov s boliami v nizhnei chasti spiny. Vrach. 2007; 5: 56–9. [in Russian]
74. Alekseev V.V., Rachin A.P., Podchufarova E.V. Flupirtin (Katadolon) – nestandartnyi podkhod v terapii boli. Nevrol. i revmatologiia. 2009; 2: 50–3. [in Russian]
75. Danilov A.B., Nikolaeva N.S. Effektivnost novoi formy flupirtina (Katadolona forte) v lechenii ostroi boli v spine. Managepain. 2013; 1: 44–8. [in Russian]
76. Yadav G, Behera SS, Das SK et al. Role of flupirtine as a preemptive analgesic in patients undergoing laparoscopic cholecystectomy. J Anaesthesiol Clin Pharmacol 2015; 31 (2): 169–73.
77. Ueberall MA, Essner U, Müller-Schwefe GH. 2-week efficacy and tolerability of flupirtine MR and diclofenac in patients with acute low/back pain-results of a post-hoc subgroup analysis of patient-level data from four non-interventional studies. MMW Fortschr Med 2013; 155 (Suppl. 4): 115–23.
78. Li C, Ni J, Wang Z et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008; 24 (12): 3523–30.
79. Uberall MA, Mueller-Schwefe GH, Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr Med Res Opin 2012; 28 (10): 1617–34.
80. Rachin A.P. Desiat dokazatelstv uspeshnogo primeneniia flupirtina (katadolona) pri boliakh v nizhnei chasti spiny. Lechenie nervnykh boleznei. 2007; 2: 35–9. [in Russian]
81. Restrictions in the use of flupirtine-containing medicines – CMDh endorses PRAC recommendation. Press release. 28/06/2013. URL: http://www.ema.europa.eu/ema/
index.jsp curl=pages/news_and_events/news/2013/06/news_detail_001831.jsp&mid=WC0b01ac058004d5c1
82. Restrictions in the use of flupirtine-containing medicines. 13 September 2013. EMA/563900/ 2013. URL: http://www.ema.europa.eu/docs/en_GB/document_library/ Referrals_document/Flupirtine-containing_medicines/European_Commission_final_decision/ WC500155310.pdf
83. Harish S, Bhuvana K, Bengalorkar GM, Kumar T. Flupirtine: Clinical pharmacology. J Anaesth Clin Pharmacol 2012; 28: 172–7.
84. Treudler R, Pohle K, Simon JC. Flupirtine is a safe alternative drug in patients with hypersensitivity to NSAIDs. Eur J Clin Pharmacol 2011; 67 (9): 961–3.
85. Flupirtine (флупиртин). URL: https://www.vidal.ru/drugs/molecule/1338 / Flupirtine (flupirtin). URL: https://www.vidal.ru/drugs/molecule/1338 [in Russian]
86. Wörz R. Long-term-treatment of chronic pain patients with flupirtine – on hepatotoxicity and persistent effectiveness from 7 months to 22 years. MMW Fortschr Med 2014; 156 (Suppl. 4): 127–34.
87. Nicoletti P, Werk A, Sawle A et al. International Drug-induced Liver Injury Consortium. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics 2016; 26 (5): 218–24.
88. Trukhan D.I. Ratsionalnaia farmakoterapiia v gastroenterologii. Handbook for Practitioners Doctors. 2012; 10: 18–24. [in Russian]
89. Tarasova L.V., Trukhan D.I. Lekarstvennaia bezopasnost v gastroenterologii. Eksperim. i klin. gastroenterologiia. 2013; 4: 81–7. [in Russian]
90. Trukhan D.I, Tarasova L.V. Lekarstvennaia bezopasnost i ratsionalnaia farmakoterapiia v gastroenterologicheskoi praktike. Klin. perspektivy gastroenterologii, gepatologii. 2013; 5: 9–16. [in Russian]
Авторы
Д.И.Трухан
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12 dmitry_trukhan@mail.ru
________________________________________________
D.I.Trukhan
Omsk State Medical University of the Ministry of Health of the Russian Federation. 644099, Russian Federation, Omsk, ul. Lenina, d. 12 dmitry_trukhan@mail.ru